Eavi2020
Funded by the EC, the European AIDS Vaccine Initiative (EAVI2020) is a new 23 million euro initiativ
Financed by the EU’s Horizon 2020 Programme, the European AIDS Vaccine Initiative (EAVI2020) brings together leading HIV researchers from public organisations and biotech companies from across Europe, Australia, Canada and the USA in a focused effort to develop protective and therapeutic HIV vaccines. According to the World Health Organisation, around 35 million people were living with HIV at the
28/07/2021
👋 We caught up with some of our past - Athina, Philipp, Yoann, Narcis and Dominik - to see where they are now and how their experiences from the EAVI2020 training programme have kick-started their careers in HIV research!
https://www.eavi2020.org/eavi2020-students-in-focus-revisited/
06/07/2021
'This new strategy is what makes this trial so exciting, it’s being tested in HIV negative people for prevention, but also HIV positive patients for a cure.'
Eavi2020 begins new of novel mosaic HIV vaccine led by Dr Paola Cicconi, Prof Tomáš Hanke, and team, at University of Oxford
Featured on ITV News 📽️ https://www.itv.com/news/2021-07-05/how-the-covid-jab-paved-the-way-for-a-promising-new-hiv-vaccine-trial
How the Covid jab paved the way for a promising new HIV vaccine trial | ITV News Trials of a new HIV vaccine have begun at Oxford University, building on the success of the Covid vaccine developed by the institution. | ITV National News
06/05/2021
👏👏 Another belated, but very well deserved, congratulations to PhD student Luis Romero-Martín from IrsiCaixa, for winning the New Investigators Award at HIV Research For Prevention - HIV R4P earlier this year.
Well done Luis from the whole Eavi2020 consortium!! 🎉
More information on the winning abstract 🏅👇https://www.hivr4p.org/meet-the-award-winners/
27/04/2021
'Following a challenging year in the face of the pandemic the consortium is excited to be progressing again at full speed.' Prof Robin Shattock in our quarterly newsletter.
Explore the latest news from the 💉search, from the resume of clinical trials to our Narcís Saubi, in the April 2021 newsletter here 👉 https://www.eavi2020.org/eavi2020-quarterly-newsletter-april-2021/
23/04/2021
A huge congratulations albeit a belated one to Nathifa Moyo from our partners at the University of Oxford, for winning a new investigators award at the recent HIVR4P Conference. Nathifa won for her abstract “Tetravalent immunogen assembled from conserved regions of HIV-1 and delivered as mRNA demonstrates potent preclinical T-cell immunogenicity and breadth”. Well done Nathifa! More info on her abstract https://hivr4p.org/meet-the-award-winners/
19/04/2021
'I left academia, and went to the veterinary vaccines industry (no, it’s not the dark side of science). I learnt a lot on viruses, vaccines, production methods, trials, challenges… It was real “from bench to farm-side” research'
👋 Meet Narcís Saubi from Vall d'Hebron Research Institute (VHIR) our
👉 https://eavi2020.org/eavi2020-students-in-focus-narcis-saubi-from-universitat-autonoma-de-barcelona-spain/
EAVI2020 Students in Focus: Narcís Saubi from Vall d'Hebron Research Institute (VHIR), Spain - EAVI2020 Hello everybody. I’m Narcís Saubi. I’m a chemist, and proud of it. I studied chemistry in Girona and specialized in Biochemistry at Universitat Autonoma de Barcelona.
19/03/2021
New paper in The Lancet Global Health on PopART trial showed that a combination prevention package including universal HIV testing and treatment, is cost-effective and can cut the incidence of cases in high-prevalence communities. https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00034-6/fulltext
16/03/2021
PROJECT UPDATE: EAVI2020 extended and trials resume
EAVI2020 clinical work is coming out of its semi-hibernating state and the prospects seem brighter for 2021 as just this past month, EAVI2020’s funding body, the European Commission has given EAVI2020 an extra 12 months of breathing space. We have such an amazing consortium and they are keen to get EAVI2020 HIV vaccine design and development research back on track. A very big thank you to the Research Project Management team at Imperial College London for all your hard work in the extension management process! More details on this huge project news at EAVI2020's website https://www.eavi2020.org/eavi2020-extended-and-trials-resume/
EAVI2020 extended and trials resume - EAVI2020 A new year, and a very different landscape from the last. EAVI2020 clinical work is coming out of its semi-hibernating state and the prospects seem brighter for 2021. Just this past month, EAVI2020’s funding body, the European Commission has given EAVI2020 an extra 12 months of breathing space.
10/03/2021
Our chief investigator, Prof Robin Shattock profiled in The Lancet, one of the world's oldest and best-known general medical journals. Prof Shattock speaks about his journey to becoming one of the leading researchers in innovative vaccine technology and his current vaccine research in battling two pandemics: the everchanging novel COVID-19 and the 30+ year HIV/AIDS by way of EAVI2020. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00510-9/fulltext
19/02/2021
Our project partners, CEA (French Alternative Energies and Atomic Energy Commission) in the Infectious Disease Models and Innovative Therapies centre (IDMIT)are advertising for a post-doc to work on the vaccination project funded by the Gates Foundation. 2-year post to start immediately. Applications close March 1st. More info and to apply via the link. https://www.eavi2020.org/post-doc-opportunity-in-paris-sars-cov-2-vaccination-project-with-bill-melinda-gates-foundation/
Post-doc opportunity in Paris - SARS-CoV-2 vaccination project with Bill & Melinda Gates Foundation - EAVI2020 Our partners at CEA in the Infectious Disease Models and Innovative Therapies department (IDMIT) have a post-doc opportunity on a SARS-CoV-2 vaccination project with the Bill & Melinda Gates Foundation. This amazing opportunity is available immediately.
03/02/2021
Tune-in for EAVI2020 researcher, Dr Katrina Po***ck. Kat will discuss clinical trials on native-like trimers based on consensus and mosaic envelope sequences @ 16:45 UTC. https://programme.hivr4p.org/Programme/Session/32
On , Prof Robin Shattock at Imperial College London says "We need the world to remember that still has an enormous toll on the human population...We really hope that the success in the COVID-19 space will accelerate the discovery of a badly needed HIV vaccine."
EAVI2020 partners at the Infectious Disease Models and Innovative Therapies unit at CEA France, Dr Pauline Maisonnasse and Dr Nathalie Bosquet explain on that HIV vaccine research has progressed the : "We were able to continue using adjuvants and vaccine structures already tested in the framework of EAVI2020." But we must never forget that 40 years on, and we still do not have an efficacious HIV vaccine. The EAVI2020 partners are certain that the new technologies developed to fight COVID-19 will be harnessed to progress and advance the search for an HIV vaccine.
Dr Behazine Combadière, a lead investigator at the Centre for Immunology and Infectious Diseases at INSERM in Paris, France is working on predicting the effectiveness of a vaccine against which is concurrently advancing the development research.
World AIDS Day and another pandemic. EAVI2020 researchers have come together to explain how developing an HIV vaccine has informed design. Dr Joan Joseph Munné explains the work they are doing at the Vall d'Hebron Research Institute in Barcelona. and donate at https://www.worldaidsday.org/
Dec 1 is World AIDS Day. EAVI2020 researchers have come together to explain how developing an HIV vaccine has informed design. Seng Kuong Ung, a lab technician at Imperial College London, UK tells us about lessons learnt with and applying them to combatting . Give your support at https://www.worldaidsday.org/
24/11/2020
EAVI2020 PhD students in focus: Meet Alessandra Gallinaro, a Postdoc Researcher at the Istituto Superiore di Sanità (ISS) in Rome, Italy. Alessandra has a PhD in Experimental Medicine. Of the EAVI2020 training programme she comments she was able to interact and exchange views with some of the most important people in the HIV research field. Read more https://www.eavi2020.org/eavi2020-students-in-focus-alessandra-gallinaro-from-the-istituto-superiore-di-sanita-iss-in-italy/
19/11/2020
The EAVI2020 10th PhD training course was a huge success. 60 PhD students & researchers from around the globe learnt about limitations & hurdles of glycoprotein vaccine design, production & purification. An interesting item was comparing & glycoprotein vaccine development. A big thanks to The Academic Medical Center team for organising and to the speakers for their exceptional talks.
16/11/2020
EAVI2020 Students in Focus: Time to meet Dominik Damm. "I wished to work in the field of since I was 13 years old". Dominik is in his 6th year of study and his research focusses on T helper nanoparticles as HIV vaccine candidates. https://www.eavi2020.org/eavi2020-students-in-focus-dominik-damm-academic-medical-center-amc-the-netherlands/
04/11/2020
Prof Robin Shattock spoke to The Community Research and Development Information Service (CORDIS) recently. They are the European Commission's primary source of results from the projects funded by the EU's framework programmes for research and innovation (FP1 to Horizon 2020). "The project’s prototype RNA vaccines not only show promise for HIV treatment: they also have had a positive impact on vaccine development for COVID-19.
We spoke with Shattock to discuss the project’s continued importance and achievements so far."
The worldwide push for a can’t make us forget about 30 years of efforts to identify one for .
Robin Shattock from Imperial College London leads one of the research groups under the Eavi2020 project. The project’s prototype vaccines not only show promise for , but they also have had a positive impact on vaccine development for COVID-19.
We spoke with Shattock to discuss the project’s continued importance and achievements so far.
Click here to read the interview 👉 http://bit.ly/cordis-hiv-vaccine
Image credits: © Syda Productions, Shutterstock
30/10/2020
And that's a wrap on the first ever VIRTUAL EAVI2020 annual meeting! Congrats to the EAVI2020 consortium for such fantastic presentations wrapping up all the research and work that has happened in EAVI2020's fifth year. A shout out to Imperial College London Research Project Management Office for organising; couldn't have been easy with an 80+ strong consortium! A massive kudos to Prof Robin Shattock for leading such an amazing group of people dedicated to developing an .
29/10/2020
EAVI2020 annual meeting underway! A pity we can't be together in person, but our 80+ strong consortium are ready to share with each other the EAVI2020 HIV vaccine design and development work they have been doing the past year. GoToMeeting won't let > 25 webcams on, but we will work out a way to see everyone!
22/09/2020
"The lessons learned with prototype RNA of vaccines in this [EAVI2020] European project have informed design elements that we are now applying to COVID-19" - Prof Robin Shattock recognises the European collaborative efforts in EAVI2020 to develop an effective HIV vaccine as he presented to the European Parliament ENVI-ITRI committee, "How to secure access to COVID-19 vaccines for EU citizens: clinical trials, production and distribution challenges". Similarly, "...our experience gained in developing a vaccine against COVID-19 will inform future HIV vaccine design. Therefore those early investments...we will bring back knowledge and technology to the existing HIV program".
To watch the public hearing in full: https://www.europarl.europa.eu/streaming?event=20200922-0900-COMMITTEE-ENVI-ITRE&start=2020-09-22T07:00:05Z&end=2020-09-22T08:08:46Z&language=en
27/08/2020
EAVI2020 quarterly newsletter just out. Get all the latest news and project updates from the EAVI2020 consortium who are accelerating the search for an effective HIV vaccine. https://eavi2020.org/eavi2020-quarterly-newsletter-august-2020/.
EAVI2020 quarterly newsletter | August 2020 - EAVI2020 The EAVI2020 quarterly newsletter, August 2020 is available to download.
25/08/2020
EAVI2020 Students in Focus: Meet Ehsan Suleiman. Ehsan is an employee of Polymun Scientific (Austria) and is a PhD student of Biomolecular Technology of Proteins (BioToP) at the University of Natural Resources and Life Sciences in Vienna, Austria. Ehsan has been involved in the development of readily scalable approaches for the manufacturing of liposomes-based vaccines against HIV-1 for almost five years now. Read more: https://www.eavi2020.org/eavi2020-students-in-focus-ehsan-suleiman-polymun-scientific-austria/
18/08/2020
Prof Tomáš Hanke, EAVI2020 PI at the University of Oxford
Scientia on HIV vaccine development; including his work on T cell response to second-generation conserved immunogen, HIVconsvX, and its predecessor, HIVconsv. https://scientia.global/professor-tomas-hanke-use-of-experimental-medicine-for-rational-development-of-an-effective-hiv-vaccine/
Professor Tomáš Hanke - Use of Experimental Medicine for Rational Development of an Effective HIV Vaccine • scientia.global The UNAIDS estimates that 38 million people currently live with human immunodeficiency virus (HIV) infection. Combination antiretroviral treatment has had great success in saving lives but is also associated with numerous medical and public health challenges. Vaccination remains the best and most co...
04/08/2020
EAVI2020 Students in Focus: Meet Isabella Huettner. Isabella completed 4 years of her PhD with Dr. Katie Doores at King’s College London (UK) studying the role of sugars as priming immunogens for an HIV-1 vaccine. She recently submitted her PhD thesis and will have her viva soon. Congratulations and good luck with the viva, Isabella! https://www.eavi2020.org/eavi2020-students-in-focus-isabella-huettner-kings-college-london-uk/
EAVI2020 Students in Focus: Isabella Huettner (King's College London, UK) - EAVI2020 Isabella Huettner is a PhD student at King’s College London, UK under Dr Katie Doores and has focussed her PhD on the role of sugars as priming immunogens for a HIV-1 vaccine.
29/07/2020
EAVI2020 has received a 6-month cost-neutral extension from the European Commission as a result of the necessary halting of EAVI2020 lab work due to COVID19. EAVI2020 will thus have an expected project closure date in April 2021. More at https://www.eavi2020.org/
COVID-19 UPDATE: - EAVI2020 29 July 2020 EAVI2020 has received a 6-month […]
02/07/2020
Our very own Prof Robin Shattock will be on the panel discussion for satellite "HIV vaccine: the search goes on!"
Tues 7 Jul 6PM (CEST)
Led by Roger Tatoud, International Aids Society, Prof Shattock will be sharing insights on EAVI2020 HIV vaccine design and development research along with global R&D. Prof Shattock will be joining:
Mitchell Warren, AVAC
Luc Debruyne, CEPI
Martin Friede, WHO
Maureen Luba, AVAC / COMPASS
https://iascslide.ctimeetingtech.com/aids2020/attendee/confcal_6/show/session/511
27/05/2020
EAVI2020 May newsletter | special COVID-19 edition. EAVI2020 clinical trials have been placed on hold but here in this issue, we take a look at the research EAVI2020's partners are doing to help combat COVID-19. https://www.eavi2020.org/eavi2020-may-newsletter-special-covid-19-edition/
EAVI2020 May newsletter | special COVID-19 edition - EAVI2020 Download the May 2020 newsletter (.pdf opens in […]
30/04/2020
EAVI2020 Students in Focus: Meet Nathifa Moyo. It’s that time again to shine a light on EAVI2020’s students. Nathifa is a Senior Postdoctoral Immunologist at University of Oxford (UK) focussing on Studies on HIV-1 vaccine development. https://www.eavi2020.org/eavi2020-students-in-focus-nathifa-moyo/
EAVI2020 Students in Focus: Nathifa Moyo (University of Oxford, UK) - EAVI2020 It’s that time again to shine a light …
30/04/2020
EAVI2020 Students in Focus: Meet Philip Mundsperger. It’s that time again to shine a light on EAVI2020’s students. So turn off the barrage of incoming COVID-19 news and meet some of EAVI2020's early-career researchers. Philipp Mundsperger is a PhD student at Polymun Scientific and the University of Natural Resources and Life Sciences (Austria) https://www.eavi2020.org/eavi2020-students-in-focus-philipp-mundsperger-polymun-scientific-austria/
EAVI2020 Students in Focus: Philipp Mundsperger (Polymun Scientific, Austria) - EAVI2020 Let’s meet Philipp Mundsperger. Hi! My name is …
23/03/2020
update from Prof Robin Shattock
EAVI2020 coordinator and on behalf of the EAVI2020 consortium. To further ensure the safety and well-being of all, EAVI2020 clinical studies have been placed on hold. For the full update, go to https://eavi2020.org
10/03/2020
The EAVI2020 photo exhibition, which illustrates the journey of developing an through powerful images, continues its journey around Europe. https://www.eavi2020.org/eavi2020-photo-exhibition-travels-to-hungary/
EAVI2020 photo exhibition travels to Hungary - EAVI2020 The development of an HIV vaccine in photos …
25/02/2020
EAVI202's mosaic trial commences. The team
at Imperial College London will test the immune response to the most vulnerable parts of the virus using different combos of synthetic HIV envelope proteins. We sit down with Dr Katrina Po***ck, who is a senior clinician working on the mosaic trials at Imperial, to learn more about the trial and its intended research impact.
https://www.eavi2020.org/eavi2020-gets-clinical-the-mosaic-trial/
19/02/2020
EAVI2020 students in focus. Meet Athina Kilpeläinen who has worked in labs at Vall d’Hebron Research Institute (VHIR) in Barcelona, Spain and Karolinska Institutet in Stockholm, Sweden as part of EAVI2020's Continuing Education & Training in HIV vaccine development programme. https://eavi2020.org/eavi2020-students-in-focus-athina-kilpelainen-karolinska-institutet-sweden/
EAVI2020 Students in Focus: Athina Kilpeläinen (Karolinska Institutet, Sweden) - EAVI2020
11/02/2020
EAVI2020 students in focus. As part of EAVI2020's Continuing Education & Training in HIV vaccine development programme, we shine a light on the students who have worked tirelessly in the EAVI2020 project. Here is PhD graduate, Yoann Aldon
https://eavi2020.org/eavi2020-students-in-focus-yoann-aldon/
27/01/2020
BBC Radio 4's Today programme (25 January) interviewed Professor Robin Shattock, EAVI2020 coordinator, about coronavirus. Professor Shattock said: "We have two vaccine candidates that we've produced in our laboratory and we'll have these in animal models by the middle of next February. We are ready, if called upon, to rapidly move these into human studies if at some point someone wants us to respond."
https://www.bbc.co.uk/sounds/play/m000dr9s (from 32m 14s)
Today - 25/01/2020 - BBC Sounds Including Sports Desk, Weather and Thought for the Day.
17/01/2020
EAVI2020’s coordinator, Prof Robin Shattock of Imperial College London (UK) speaking at The Vaccinology Club of the French Society for Immunology conference this morning. A pillared focus of the conference is the development of new vaccine approaches and new methods for monitoring the effectiveness of vaccines such as systems vaccinology. Prof Shattock sharpened this focus to HIV Experimental Medicine studies.
https://www.alphavisa.com/vcm/2020/
10/01/2020
EAVI2020 is excited to share the HIV VACCINE symposium organised by EAVI2020 researcher, Prof Rogier Sanders, is 22-26 March 2020. Prof Robin Shattock, coordinator of EAVI2020 will be speaking and focussing on vaccine design and vaccine trials. More info and to register http://keystonesymposia.org/20x5
Videos (show all)
